Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.35 |
| ▸ | MPC2 | O95563 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19559787 | 0.82 | PPARG (0.50) | PPARGMCL1FFAR1MPC2CYP2C8 | |
| SCHEMBL19559681 | 0.78 | PPARG (0.41) | PPARGMCL1FFAR1 | |
| SCHEMBL19559701 | 0.76 | PPARG (0.51) | PPARGMCL1FFAR1MPC2CYP2C8 | |
| SCHEMBL19559725 | 0.76 | PPARG (0.40) | PPARGMCL1FFAR1CYP2C9 | |
| SCHEMBL6930420 | 0.75 | PPARG (0.54) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL15811536 | 0.75 | PPARG (0.69) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213637 | 0.75 | PPARG (0.39) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14299373 | 0.74 | PPARG (0.49) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213709 | 0.74 | PPARG (0.38) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL17540550 | 0.73 | PPARG (0.37) | PPARGFFAR1MPC2CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513070-B1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |